Cargando…

ED SUM: Triple-negative breast cancer is inhibited by depleting mitochondrial copper in mice.: Mitochondrial copper depletion suppresses triple-negative breast cancer in mice

Depletion of mitochondrial copper, which shifts metabolism from respiration to glycolysis and reduces energy production, is known to be effective against cancer types that depend on oxidative phosphorylation. However, existing copper chelators are too toxic or ineffective for clinical application. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Liyang, Gouw, Arvin M., LaGory, Edward L., Guo, Shenghao, Attarwala, Nabeel, Tang, Yao, Qi, Ji, Chen, Yun-Sheng, Gao, Zhou, Casey, Kerriann M., Bazhin, Arkadiy A., Chen, Min, Hu, Leeann, Xie, Jinghang, Fang, Mingxi, Zhang, Cissy, Zhu, Qihua, Wang, Zhiyuan, Giaccia, Amato J., Gambhir, Sanjiv Sam, Zhu, Weiping, Felsher, Dean W., Pegram, Mark D., Goun, Elena A., Le, Anne, Rao, Jianghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956242/
https://www.ncbi.nlm.nih.gov/pubmed/33077961
http://dx.doi.org/10.1038/s41587-020-0707-9
Descripción
Sumario:Depletion of mitochondrial copper, which shifts metabolism from respiration to glycolysis and reduces energy production, is known to be effective against cancer types that depend on oxidative phosphorylation. However, existing copper chelators are too toxic or ineffective for clinical application. Here we develop a safe, mitochondria-targeted, copper-depleting nanoparticle (CDN) and test it against triple-negative breast cancer (TNBC). We show that CDNs decrease oxygen consumption and oxidative phosphorylation, cause a metabolic switch to glycolysis, and reduce ATP production in TNBC cells. This energy deficiency, together with compromised mitochondrial membrane potential and elevated oxidative stress, results in apoptosis. CDNs should be less toxic than existing copper chelators because they favourably deprive copper in the mitochondria in cancer cells instead of systemic depletion. Indeed, we demonstrate low toxicity of CDNs in healthy mice. In three mouse models of TNBC, CDN administration inhibits tumor growth and substantially improves survival. The efficacy and safety of CDNs suggest the potential clinical relevance of this approach.